Business Description
Biomarin Pharmaceutical Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
BMRN.AustriaB1MR34.BrazilBM8.GermanyBMRN.Mexico0HNC.UKBMRN.USA Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.17 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | 4.97 | |||||
| Interest Coverage | 0.23 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 7.94 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.3 | |||||
| 3-Year EPS without NRI Growth Rate | 7.3 | |||||
| 3-Year Book Growth Rate | 11.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 48.58 | |||||
| Future 3-5Y Total Revenue Growth Rate | 15.12 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.79 | |||||
| 9-Day RSI | 53.57 | |||||
| 14-Day RSI | 61.34 | |||||
| 6-1 Month Momentum % | 8.5 | |||||
| 12-1 Month Momentum % | 21.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.15 | |||||
| Quick Ratio | 3.54 | |||||
| Cash Ratio | 2.44 | |||||
| Days Inventory | 606.26 | |||||
| Days Sales Outstanding | 75.05 | |||||
| Days Payable | 151.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.29 | |||||
| Operating Margin % | 0.29 | |||||
| Net Margin % | 4.18 | |||||
| ROE % | 1.91 | |||||
| ROA % | 1.38 | |||||
| ROIC % | 0.1 | |||||
| ROC (Joel Greenblatt) % | 6.2 | |||||
| ROCE % | 2.08 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 259.03 | |||||
| Forward PE Ratio | 39.53 | |||||
| PE Ratio without NRI | 265.02 | |||||
| PS Ratio | 10.18 | |||||
| PB Ratio | 4.43 | |||||
| Price-to-Tangible-Book | 5.15 | |||||
| Price-to-Free-Cash-Flow | 462.95 | |||||
| Price-to-Operating-Cash-Flow | 110.91 | |||||
| EV-to-EBIT | 172.52 | |||||
| EV-to-Forward-EBIT | 48.25 | |||||
| EV-to-EBITDA | 91.27 | |||||
| EV-to-Forward-EBITDA | 38.15 | |||||
| EV-to-Revenue | 9.98 | |||||
| EV-to-Forward-Revenue | 8.23 | |||||
| EV-to-FCF | 503.1 | |||||
| Price-to-Projected-FCF | 6.67 | |||||
| Price-to-Median-PS-Value | 0.83 | |||||
| Price-to-Graham-Number | 7.79 | |||||
| Price-to-Net-Current-Asset-Value | 20.97 | |||||
| Earnings Yield (Greenblatt) % | 0.58 |
How Biomarin Pharmaceutical Inc (MEX:BMRN) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Details
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 40,905.693 | ||
| EPS (TTM) (MXN) | 8.446 | ||
| Beta | 0 | ||
| Volatility % | 26.87 | ||
| 14-Day RSI | 61.34 | ||
| 14-Day ATR (MXN) | 2.640535 | ||
| 20-Day SMA (MXN) | 2077.47 | ||
| 12-1 Month Momentum % | 21.88 | ||
| 52-Week Range (MXN) | 1490 - 2132.23 | ||
| Shares Outstanding (Mil) | 185.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biomarin Pharmaceutical Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biomarin Pharmaceutical Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||